RankingsPricing
  1. US-listed companies
  2. VERTEX PHARMACEUTICALS INC
  3. Financials
  4. Cash from investing

VERTEX PHARMACEUTICALS INCVRTX

Market cap
$108.9B
P/E ratio
SummaryFinancials
Period EndCash from investing (Million USD)YoY (%)
Dec 31, 2024-3,770+20.00%
Dec 31, 2023-3,142+878.42%
Dec 31, 2022-321-5.81%
Dec 31, 2021-341-443.00%
Dec 31, 202099-108.05%
Dec 31, 2019-1,235+511.07%
Dec 31, 2018-202-53.81%
Dec 31, 2017-438-518.96%
Dec 31, 2016104-61.14%
Dec 31, 2015269+263.52%
Dec 31, 201474-236.63%
Dec 31, 2013-54-87.29%
Dec 31, 2012-426-300.47%
Dec 31, 2011212+2809.35%
Dec 31, 20107

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)